Cedar Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Cedar Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-40	Closed	-$28.9K	–	310
2022 Q4	$28.9K	Hold	40	–	–	0.01%	179
2022 Q3	$28K	Sell	40 -201	-83%	-$127K	0.01%	200
2022 Q2	$142K	Hold	241	–	–	0.07%	120
2022 Q1	$168K	Hold	241	–	–	0.07%	120
2021 Q4	$152K	Hold	241	–	–	0.06%	135
2021 Q3	$146K	Hold	241	–	–	0.06%	121
2021 Q2	$135K	Buy	241 +57	+31%	+$28.9K	0.06%	126
2021 Q1	$87K	Buy	+184	New	+$89.6K	0.04%	133

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Cedar Wealth Management's REGN Position: Q1 2023 in Review

Cedar Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2023, closing a stake of 40 shares — an estimated $28.9K sold.

Cedar Wealth Management first reported a position in REGN in Q1 2021 and held it in 8 quarters. The position peaked at $168K in Q1 2022. 1,191 funds tracked by Wall St. Rank hold REGN as of Q1 2023.

Cedar Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Cedar Wealth Management sold 40 Regeneron Pharmaceuticals shares in Q1 2023, an estimated $28.9K.
Cedar Wealth Management first reported a position in Regeneron Pharmaceuticals in Q1 2021 and held it in 8 quarters.
Cedar Wealth Management's Regeneron Pharmaceuticals position peaked at $168K in Q1 2022.
1,191 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2023.

Based on Cedar Wealth Management's 13F filing for Q1 2023, filed 15 May 2023.